Testosterone Replacement Therapy and Liraglutide Effects on Weight Loss in Hypogonadism.
NCT03619330 on ClinicalTrials.gov · last registry update 2018-08-07
A small phase 4 — 30 participants, against a typical 75. The sponsor logged completion for August 2015. Primary outcome, as filed: The main outcome was improvements of symptoms related to hypogonadism. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2014-12
- Primary completion
- 2015-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The main outcome was improvements of symptoms related to hypogonadism
Conditions studied
Hypogonadism · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.